Recently, bioGenous(Suzhou) announced the successful completion of its nearly 100 million RMB Series A financing. This round was led by SDIC Fund, with existing shareholder Marathon Venture Partners making an oversized follow-up investment. With this financing, bioGenous aims to further enhance its globally leading CDMO and CRO technical systems for organoids, accelerate the construction and operation of its commercial production base, and expand into overseas markets.

bioGenous Multilineage, Multicancer Standardized Organoid Technology

bioGenous focuses on cutting-edge innovations in organoid technologies, with globally leading capabilities in organoid model construction. The company is dedicated to providing standardized, modular organoid products and technical support for biomedical research, drug development, and clinical precision medicine. bioGenous’ scientific team has pioneered the world's first human organoid COVID-19 infection model, medulloblastoma model, and other disease models and drug development platforms. The company also developed the world’s first automated organoid biobank and high-throughput drug screening platform, along with innovative organoid models based on tissue and tumor microenvironment analysis. Additionally, bioGenous offers comprehensive products such as multilineage, multicancer organoid reagents, reagent kits, and whole-process CDMO and CRO services.

bioGenous now operates a 3,000 square meter R&D and production facility, with major R&D and operation centers in Suzhou, Shanghai, and Dezhou. In 2023, its 10,000 square meter large-scale industrial production base will be fully operational, featuring four GMP-B grade reagent and kit production lines, six GMP-C grade organoid technical service lines, and dozens of cleanrooms. To date, bioGenous has served over 300 pharmaceutical companies, leading hospitals, and research institutes, providing organoid automation equipment, multi-tissue whole-process reagent kits, organoid culture and biobank construction solutions, organoid drug development, and precision medicine subsystems.

With this round of funding, bioGenous will continue strengthening its capabilities in multilineage, multicancer organoid construction, gene manipulation, drug discovery and efficacy evaluation, and experimental animal transplantation platforms. The company will significantly expand production capacity and lead a revolution in biomedical modeling across various fields. The financing will also support bioGenous in its global expansion, accelerating the development of its proprietary end-to-end organoid technology and promoting its application in the pharmaceutical industry.

bioGenous Founding Team’s states that “We are deeply grateful to SDIC Fund Management and Marathon Venture Partners for their trust and support. The application value of organoid technology has been highly recognized in both basic scientific research and the pharmaceutical industry. Its high degree of biomimicry makes organoids an essential tool in new drug development, precision medicine, and regenerative medicine. Moving forward, bioGenous will focus on advancing organoid technologies, developing innovative models, and building high-capacity, high-standard production pipelines to create a comprehensive organoid service ecosystem that drives life science research and accelerates the pharmaceutical industry's progress.”

SDIC Fund Management Team states that “Organoid technology is a revolutionary frontier in biomedicine with tremendous growth potential and industrial demand. SDIC Fund Management recognizes bioGenous’ deep expertise in organoid research and development. We will leverage our long-established biopharmaceutical industry resources to partner with bioGenous in advancing organoid technology and accelerating its commercialization, contributing to innovation in China's biopharmaceutical industry.”

About SDIC Fund
SDIC Fund Management specializes in advanced manufacturing investment, focusing on technological innovation and the value of outstanding entrepreneurs and teams. It prioritizes investment in sectors like intelligent manufacturing, new energy vehicles, life sciences, and ICT, promoting green, digital, and service-oriented development in manufacturing. The team manages assets exceeding 100 billion RMB, with investors including financial institutions, social security funds, and both state-owned and private capital.

About Marathon Venture Partners
Marathon Venture Partners (“MVP”) is a leading early-stage venture capital firm focusing on digital health. Marathon Venture Partners focuses intensively on the early-stage of entrepreneurship, creating a forward-looking framework in the three major areas: efficient access, innovative payment, and efficiency improvement of digital health. This approach aids in the transforming and upgrading of China's medical and health system by reducing costs and raising the quality of medical service, which benefits 1.4 billion people. To date, MVP’s RMB and USD funds have invested in more than 70 companies, including medical devices, mobile healthcare and services, precision diagnosis, and medical insurance companies with inniovative core technologies and innovative business models. The founding team has accumulated over RMB 3 billion in investment management.

About bioGenous
Founded in March 2021 and restructured in September 2022, bioGenous is headquartered in Suzhou Industrial Park. The company provides standardized organoid products and integrated technical services, covering applications in basic research, precision medicine, and drug development. bioGenous is committed to leading pharmaceutical innovation and sharing the value of models, with a mission to be the world’s leading organoid model platform, driving innovation through top-tier talent and efficient services to accelerate drug discovery and research, bringing therapies to patients faster.